This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK CMA’s drug-case trial quizzing didn’t establish wrongdoing, Auden, Actavis tell judges

By Simon Zekaria ( July 16, 2024, 16:08 GMT | Insight) -- The quizzing of Advanz’s former chief executive by the UK competition agency at trial didn’t establish unlawfulness to rebuff appeals over a drug-pricing infringement case that led to sanctions for a clutch of companies, drugmakers Auden Mckenzie and Actavis told UK appeal judges today. The arguments came in the midst of a multiday hearing at the Court of Appeal over the case.The cross-examination of Advanz’s former chief executive by the UK Competition and Markets Authority at trial didn’t establish unlawfulness to rebuff appeals over a drug-pricing infringement case that led to sanctions for a clutch of companies, Auden Mckenzie and Actavis told UK appeal judges today....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections